SARS-CoV-2 Variants: A Synopsis of In Vitro Efficacy Data of Convalescent Plasma, Currently Marketed Vaccines, and Monoclonal Antibodies.

Daniele Focosi Marco Tuccori Andreina BajFabrizio Maggi

Published in: Viruses (2021)

We summarize here in vitro evidences of efficacy for convalescent plasma, currently approved vaccines and monoclonal antibodies against SARS-CoV-2 variants of concern (VOC: B.1.1.7, B.1.351, P.1, and B.1.617.2), variants of interest (VOI: B.1.427/B.1.429, P.2, B.1.525, P.3, B.1.526, and B.1.671.1), and other strains (B.1.1.298 and B.1.258delta). While waiting from real world clinical efficacy, these data provide guidance for the treating physician.

Keyphrases

sars cov
copy number
respiratory syndrome coronavirus
electronic health record
primary care
emergency department
big data
escherichia coli
gene expression
data analysis
deep learning
drug administration